Article Text

Download PDFPDF
Epidermal lidocaine safely reduced pain in children having venipuncture at the antecubital fossa

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In children having venipuncture at the antecubital fossa, what is the optimal configuration of a single use, needle free, drug system (ALGRX 3268) that delivers powdered lidocaine into the epidermis for rapid production of local anaesthesia?

Clinical impact ratings Paediatrics ★★★★★★☆


Embedded ImageDesign:

randomised, placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients, healthcare providers, data collectors, and outcome assessors).*

Embedded ImageFollow up period:

pain was measured immediately after treatment with lidocaine or placebo and again after venipuncture.

Embedded ImageSetting:

a single centre (country not stated).

Embedded ImagePatients:

145 children 3–18 years of age (median age 10 y, 50% boys) having venipuncture at the antecubital fossa who had sufficient cognitive skills to identify faces representing the extremes of pain. Exclusion criteria included a history of allergic reactions to local anaesthetic, active …

View Full Text


  • * See glossary.

  • For correspondence: Dr J Lazar, AlgoRx Pharmaceuticals Inc, Secaucus, NJ, USA. jdlazar{at}

  • Source of funding: AlgoRx Pharmaceuticals Inc.